Press Center
Get an overview of Priothera’s recent news articles, and keep up-to-date with our ongoing work and results.
If you are a professional member of the media and would like to find out more about Priothera, please contact info@priothera.com.
Patient Voice 2026
Throughout Septembre Rouge 2026, Priothera SAS invited Carolina, an AML patient advocate, to share her story in a four-part video series.
From the shock of diagnosis and the journey through stem cell transplantation to life after transplant and her hopes for the future, Carolina speaks openly about what it means to live with AML — and about the challenges that remain after transplantation.
Her story gives a voice to many patients who are waiting for more effective maintenance treatments to help prevent relapse and improve long-term outcomes — and echoes Priothera’s commitment to addressing this unmet need.
Watch the four videos:
1. The day everything changed
2. The donor who gave me a second chance
3. Life after transplant
4. My wish for innovative maintenance treatment
EUROAPI and Priothera enter into CDMO collaboration to advance oncology project
Priothera – US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies
Priothera cleared to begin Japanese arm of pivotal Phase III study with mocravimod in patients with Acute Myeloid Leukemia undergoing allogeneic Hematopoietic Cell Transplant
Priothera announces first patients enrolled in pivotal MO-TRANS global Phase IIb/III study with mocravimod as an adjunctive and maintenance therapy for patients with Acute Myeloid Leukemia (AML) undergoing allogeneic Hematopoietic Cell Transplant (HCT)
Priothera – Positive mocravimod Phase Ib clinical data published in Transplantation and Cellular Therapy
